Nutrafol has become the dominant supplement brand in the US hair loss market, with celebrity endorsements and dermatologist co-marketing arrangements that have driven adoption faster than any nutraceutical in the category. The product contains a proprietary blend including saw palmetto, marine collagen, ashwagandha, curcumin, and various vitamins. Two randomised trials sponsored by the manufacturer provide the primary evidence base.

The 2018 women's pattern hair loss trial of Nutrafol Women showed a statistically significant 67% improvement in terminal hair count at 6 months versus placebo. The numbers look impressive in absolute terms. The methodological concerns are real: relatively small sample size (n=40 completers), proprietary blend that obscures which ingredients are driving effect, and effect size in the placebo arm that suggests substantial regression-to-mean. A 2022 men's trial showed more modest 12% terminal hair count improvement versus placebo.

The honest comparison: Nutrafol produces a measurable effect in the women's trial, more modest in the men's trial. It's substantially more expensive than alternative approaches, typically £80–100 per month versus £10 for generic minoxidil and saw palmetto separately. For patients who specifically want a comprehensive supplement and value the convenience of one product, it's a defensible choice. For patients seeking maximum cost-effective regrowth, the same money spent on minoxidil plus targeted nutritional supplementation produces better outcomes.